BioAlliance Pharma to resubmit Loramyc® NDA In the second quarter of 2009

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical
company focused on the treatment of opportunistic infections, on cancer and on AIDS, today
announced that based on a recent ad hoc meeting held with the FDA, the NDA for Loramyc® will be
resubmitted in the second quarter of 2009. If approved, Par Pharmaceutical/Strativa, BioAlliance
Pharma’s partner for Loramyc commercialization in the USA, could launch Loramyc® in the second
half of 2010.

090507EN_FDALoramyc